Protagonist Therapeutics (PTGX) Tops Q2 EPS by 10c

Protagonist Therapeutics (NASDAQ: PTGX) reported Q2 EPS of ($0.50), $0.10 better than the analyst estimate of ($0.60). Revenue for the quarter came in at $4.17 million versus the consensus estimate of $68 million.

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Correction: Kepler Cheuvreux Upgrades Siemens AG (SIE:GR) (SIEGY) to Hold
• HSBC Downgrades Stellantis NV (STLA:IM) (STLA) to Reduce